Cancer BiologybioRxivPreprint
RAS mutations drive proliferative chronic myelomonocytic leukemia via activation of a novel KMT2A-PLK1 axis
R. M. Carr, D. Vorobyev, T. Lasho…·M. M. Patnaik
This study identifies RAS mutations as drivers of proliferative CMML through a novel KMT2A-PLK1 axis, showing PLK1 inhibition can improve disease outcomes in patient-derived xenografts.
DOI 10.1101/2019.12.23.874487